Members of the
aldo-keto reductase (AKR) superfamily have been implicated in
prostaglandin (PG) metabolism and
prostate cancer. AKR1C3 possesses 11-ketoprostaglandin
reductase activity and is capable of converting
PGD2 to 9alpha, 11beta-PGF2alpha, whereas AKR1C2-mediated PG metabolism remains unclear. The accumulation of
PGF2alpha may generate proliferative signals to promote prostate cell growth. Levels of AKR1C2 and AKR1C3 expression are elevated in localized and advanced
prostate cancer. To study the significance of AKR1C2- and AKR1C3-mediated
PGD2 conversion in human prostate cell proliferation, we stably transfected
androgen insensitive human
prostate cancer PC-3 cells with AKR1C2 or AKR1C3
cDNA. PC-3 cells overexpressing AKR1C2 and AKR1C3 had elevated cell proliferation in response to
PGD2 stimulation as compared to mock transfectants. Overexpression of AKR1C2 or AKR1C3 did not alter levels of
PGF receptor (FP) expression. Inclusion of an FP antagonist (AL8810) significantly suppressed PGD2-stimulated PC-3 cell proliferation in these stable transfectants. In addition,
PGD2 significantly elevated levels of total Akt
protein expression and Akt Ser473 phosphorylation in AKR1C2 and AKR1C3 stable transfectants; and inclusion of a
phosphatidylinositol 3-kinase (PI3K) chemical inhibitor (
LY294002) attenuated PGD2-stimulated cell proliferation in these transfectants. Our results suggested that both AKR1C2 and AKR1C3 mediate similar
PGD2 conversion toward the accumulation of proliferative signals through FP and PI3K/Akt signaling pathways to promote prostate cell proliferation.